USE OF HIGH DOSE CIS-DICHLORODIAMMINE PLATINUM (II) (NSC-119875)+ FOLLOWING FAILURE ON PREVIOUS CHEMOTHERAPY FOR ADVANCED CARCINOMA OF THE OVARY

Publisher Website
Google Scholar
Abstract
Cis-Dichlorodiammineplatinum II (cisplatin) in high dose was given to 40 patients with advanced carcinoma of the ovary; 31 had been previously treated with alkylating agents or various chemotherapy regimens excluding cisplatin, and 9 patients had tumors resistant to low-dose cisplatin regimens. The high-dose regimen consisted of cisplatin given at 100 mg/m2 with 24 h pre- and post-treatment hydration, at monthly intervals up to maximum of 5 doses. Seventeen of the 31 patients (55%) showed a therapeutic response, including 25% who had complete regression of tumor. The median duration of complete remissions was 10 mo. Patients who had already been exposed to cisplatin at low doses (20 mg/m2) responded less well, only 2 of 9 (22%). Even at this late stage of disease, 7 patients showed a good enough response to undergo further surgery. Of these, 3 were macroscopically clear of tumor; in 2 patients, multiple biopsy material failed to show residual tumor microscopically.